Bolus Fibrinolytic Therapy in Acute Myocardial Infarction

Abstract

Given the ease of administration and the similar outcomes compared with accelerated infusion recombinant tPA, it is likely that a key component of contemporary reperfusion will include a bolus fibrinolytic.

Prothrombotic Gene Expression Profile in Vascular Smooth Muscle Cells of Human Saphenous Vein, but Not Internal Mammary Artery

“…tPA indeed induces such an effective thrombolysis that its recombinant forms have several therapeutic indications. 28 This study reveals that tPA is expressed at a much higher level in VSMCs from IMA as compared to SV. VSMC supernatant from IMA indeed exerted a lower acceleration of clotting time than supernatant from SV, and this effect seems to be induced by a lower release of TF and a concomitant higher release of TFPI as well as tPA in IMA.…”

Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial

“…26,27 Up until now, no studies comparing directly tenecteplase with reteplase have been reported. Llevadot et al 28 had indirectly compared reteplase to tenecteplase in patients with AMI (meta-analysis) and found no significant differences among them in terms of death and disabling stroke in patients with AMI. As one of the bolus thrombolytics, reteplase may be another alternative to alteplase in patients with acute ischemic stroke.…”

Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?

“…No other endpoints, such as heart failure, are provided. One later study and a review did not report on outcomes of the subgroup with inferior STEMI separately [ 15 , 16 ].…”